Agentless security for untouchable IoT devices

Tern plc

The rapid expansion of connected devices across enterprise and industrial environments presents a pressing security challenge for organisations preparing for 2026 and beyond. Increasingly, a large portion of a company’s device estate cannot be secured through traditional software agents or conventional update mechanisms. Many sensors, embedded controllers, medical instruments and legacy systems are either incapable of running additional software, cannot tolerate downtime for patching, or are geographically dispersed in remote or hostile environments.

Conventional endpoint security, built on the assumption that every device can host a monitoring agent, struggles at scale in environments where devices are resource constrained or run proprietary firmware. Attempting to retrofit traditional security tools often results in blind spots across thousands of device types from hundreds of vendors, increasing attack surface and operational complexity.

Agentless IoT security reframes this problem by decoupling protection from the devices themselves. Instead of installing security software on each endpoint, agentless solutions observe devices from the outside. They use network traffic analysis, infrastructure logs and application interfaces to discover and classify every IP‑connected device. By doing so, organisations gain visibility into assets they did not even know existed. This inventory of devices and behaviours becomes the foundation for identity‑based controls and policy enforcement that can be applied without touching the device itself.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Tern cuts H1 loss by 60% as portfolio growth and funding strengthen

Tern reduced its first-half loss by 60%, with net asset value improving and further fundraising strengthening the balance sheet. Additional funding has supported Talking Medicines and Device Authority, while continued progress across the portfolio provides further scope for value creation.

AI control of machines creates a new market for device trust

AI is beginning to control physical machines, increasing demand for technology that can verify device identity before those machines are allowed to act.

Peptide drug development expands beyond GLP-1

GLP-1 success is widening interest in peptide drug development, with the next phase focused on proving clinical value across new therapeutic areas.

Tern Plc announces 90% take-up of Open Offer

Tern Plc has received valid acceptances for 50.9 million Open Offer Shares, representing approximately 90% of the shares available. The fully underwritten offer will raise approximately £509,368 before expenses, with admission of the new shares expected on 24 September 2026.

Talking Medicines moves to capture pharma demand for better patient intelligence

Tighter US pharma advertising rules could increase demand for patient intelligence, supporting the relevance of Talking Medicines’ DrugVoice platform.

Tern portfolio company Talking Medicines launches ‘Intent to Prescribe’ DrugVoice application

Talking Medicines has launched a new DrugVoice application combining its Message Resonance Score™ with near-real-time point-of-care data to help pharmaceutical companies assess links between HCP message alignment and prescribing intent.

Search